AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Adam Ellenstein swim lead

Global update

Epic 105km swim for Parkinson’s could be new world record

My job was to swim and eat – the crew did everything else

READ MORE
Brussels Sprout Mousse lead

Recipes & Nutrition

Mousse of Brussels sprouts and onions topped with nutmeg

An exciting take on the iron-rich vegetable Brussels Sprouts

READ MORE
parkinsons-life-highlights-from-2016-lead

Perspectives

12 Parkinson’s Life highlights from 2016

The best of 2016: editor’s picks

READ MORE